About 19 results found for searched term "5-LOX-IN-3" (0.28 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M42484 | COX-2/15-LOX-IN-3 | Lipoxygenase |
| COX-2/15-LOX-IN-3 is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. | ||
| M42487 | 5-LOX-IN-3 | Lipoxygenase |
| 5-LOX-IN-3 is a 5-Lipoxygenase inhibitor (IC50: <1 μM). | ||
| M57559 | 2-(5-Benzyloxy-1h-indol-3-yl)-ethylamine | Others |
| 2-(5-Benzyloxy-1h-indol-3-yl)-ethylamine | ||
| M2332 | Zileuton | Lipoxygenase |
| A 64077; Abbott 64077 | ||
| Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively. | ||
| M10499 | FPL 62064 | Lipoxygenase |
| FPL62064 | ||
| FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and prostaglandin synthetase (cyclooxygenase, COX) with IC50 of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and seminal vesicle prostaglandin synthetase, respectively. | ||
| M10956 | PAT-1251 | Monoamine Oxidase |
| PAT-1251 is a potent, selective, orally lysanyl oxidase-like protein 2 (LOXL2) inhibitor of hLOXL2 and hLOXL3 IC50 The values were 0.71 and 1.17 μM, respectively, and the inhibition of LOXL2 in mice, rats, and dogs was strong.IC50 Values are 0.10, 0.12, and 0.16 μM, respectively; PAT-1251 can be used for studies of a variety of fibrous diseases. | ||
| M11173 | PC945 | Others |
| PC945 is a potent antifungal triazole drug that is resistant to a variety of sensitive and resistant strains of Aspergillus fumigatus. PC945 is a potent, tightly bound inhibitor of aspergilloxine 14α-demethylase (CYP51A/CYP51B) activity.IC50s are 0.23 μM and 0.22 μM, respectively. | ||
| M15061 | Atuliflapon | Lipoxygenase |
| AZD5718 | ||
| Atuliflapon (AZD5718) is a 5-lox activating protein (FLAP, 5‑Lipoxygenase activating protein) inhibitor that attenuates the 5-lipoxygenase pathway and reduces pro-inflammatory and vasoactive leukotriene (LT) production at an in vitro maximum 50% inhibitory concentration (IC50) of 39nM. | ||
| M19867 | Gatifloxacin hydrochloride | Topoisomerase |
| AM-1155 hydrochloride; CG5501 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride | ||
| Gatifloxacin (AM-1155, CG5501, BMS-206584, PD135432) hydrochloride is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases with IC50 of 13.8 μg/ml and 0.109 μg/ml for S. aureus topoisomerase IV and E. coli DNA gyrase, respectively. | ||
| M28883 | Gatifloxacin sesquihydrate | Antibiotic |
| AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate | ||
| Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). | ||
| M29270 | PXS-5153A | Monoamine Oxidase |
| PXS-5153A is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an IC50 of <40 nM for LOXL2 across all mammalian species and an IC50 of 63 nM for human LOXL3. PXS-5153A could reduce crosslinks and ameliorates fibrosis. | ||
| M29273 | CCT365623 hydrochloride | Monoamine Oxidase |
| CCT365623 hydrochloride is an orally active lysyl oxidase (LOX) inhibitor, with an IC50 of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties. | ||
| M29902 | Gatifloxacin mesylate | Antibiotic |
| AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate | ||
| Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). | ||
| M31063 | PXS-5153A monohydrochloride | Monoamine Oxidase |
| PXS-5153A monohydrochloride is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an IC50 of <40 nM for LOXL2 across all mammalian species and an IC50 of 63 nM for human LOXL3. PXS-5153A monohydrochloride could reduce crosslinks and ameliorates fibrosis. | ||
| M40148 | 1,2,3,10-Tetramethoxy-9-(2-hydroxy-4,5-dimethoxybenzyloxy)oxoaporphine | Others |
| 1,2,3,10-Tetramethoxy-9-(2-hydroxy-4,5-dimethoxybenzyloxy)oxoaporphine is an oxoaporphine alkaloid. 1,2,3,10-Tetramethoxy-9-(2-hydroxy-4,5-dimethoxybenzyloxy)oxoaporphine can be isolated from Thalictrum elegans. | ||
| M40718 | ThioLox | Others |
| ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor with a Ki value of 3.30 μM that exhibits anti-inflammatory and neuroprotective activities. | ||
| M42481 | 5-LOX-IN-2 | Lipoxygenase |
| 5-LOX-IN-2, an inhibitor of 5-lipoxygenase (5-LOX) with an IC50 of 0.33 μM, inhibits 5-LOX in a dose-dependent manner . | ||
| M42482 | h15-LOX-2 inhibitor 1 | Lipoxygenase |
| h15-LOX-2 inhibitor 1 is a human epithelial 15-lipoxygenase-2 (h15-LOX-2) inhibitor with IC50 of 0.34 μM. | ||
| M56711 | 5-LOX-IN-1 | Lipoxygenase |
| 5-LOX-IN-1 is an inhibitor of human 5-Lipoxygenase (5-LOX) with an IC50 value of 2.3 μM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
